Contact
searchSearch
HMP Global
Login
Arvind Dasari, MD
Conference Coverage
Use of ctDNA Monitoring During Colorectal Cancer Treatment to Identify Patients Eligible for Curative-Intent Metastasis-Directed Therapy
08/05/2025
Arvind Dasari, MD
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses...
08/05/2025
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Improves Health-Related Quality of Life Among Patients With MSI-H/dMMR Metastatic Colorectal Cancer
08/05/2025
Stephanie Holland
According to results from the CheckMate 8HW trial, nivolumab plus ipilimumab significantly improved health-related quality of life compared to nivolumab alone among patients with microsatellite instability-high or mismatch repair-deficient...
According to results from the CheckMate 8HW trial, nivolumab plus ipilimumab significantly improved health-related quality of life compared to nivolumab alone among patients with microsatellite instability-high or mismatch repair-deficient...
According to results from the...
08/05/2025
Oncology
Conference Coverage
Amivantamab Rechallenge Demonstrates Promise in Patients With Left-Sided Metastatic Colorectal Cancer
07/24/2025
Stephanie Holland
According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients who underwent rechallenge at least 9 months after EGFR inhibitor treatment.
According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients who underwent rechallenge at least 9 months after EGFR inhibitor treatment.
According to updated results...
07/24/2025
Oncology
Dirk Arnold, MD, PhD
Conference Coverage
Amivantamab Rechallenge for Patients With Left-Sided Metastatic Colorectal Cancer
07/24/2025
Dirk Arnold, MD, PhD
Dirk Arnold, MD, PhD, discusses updated results from the OrigAMI-1 trial, which assessed amivantamab rechallenge in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer who experienced disease progression after treatment...
Dirk Arnold, MD, PhD, discusses updated results from the OrigAMI-1 trial, which assessed amivantamab rechallenge in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer who experienced disease progression after treatment...
Dirk Arnold, MD, PhD, discusses...
07/24/2025
Oncology
Conference Coverage
Circulating Tumor DNA Methylation-Guided Postoperative Surveillance For Patients With Non-Metastatic Colorectal Cancer
07/08/2025
Allison Casey
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis of the FIND trial, ctDNA methylation-guided postoperative surveillance increased the likelihood of curative-intent treatment among patient with recurrent non-metastatic colorectal cancer.
According to an interim analysis...
07/08/2025
Oncology
Conference Coverage
TTFields Improved Pain, Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma
07/03/2025
Allison Casey
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial, the addition of tumor treating fields to gemcitabine/nab-paclitaxel improved pain and quality of life for patients with locally advanced pancreatic adenocarcinoma.
According to the PANOVA-3 trial,...
07/03/2025
Oncology
Conference Coverage
Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma
07/03/2025
Allison Casey
According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...
According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...
According to the TALENTACE...
07/03/2025
Oncology
Conference Coverage
Durvalumab Plus FLOT Improved EFS for Patients With Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
07/03/2025
Allison Casey
According to the MATTERHORN study, durvalumab plus FLOT chemotherapy demonstrated a statistically significant improvement of event-free survival for patients with resectable gastric/gastroesophageal junction adenocarcinoma, compared with...
According to the MATTERHORN study, durvalumab plus FLOT chemotherapy demonstrated a statistically significant improvement of event-free survival for patients with resectable gastric/gastroesophageal junction adenocarcinoma, compared with...
According to the MATTERHORN...
07/03/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use